FDA-Approved Therapy
UPMC Hillman Cancer Center offers the FDA-approved therapies YESCARTA™ (axicabtagene ciloleucel) and KYMRIAH™ (tisagenlecleucel).
Learn MoreUPMC Hillman Cancer Center is part of the UPMC family.
Explore this Section
UPMC Hillman Cancer Center is the first center in western Pennsylvania to offer chimeric antigen receptor (CAR) T-cell therapy, a type of immunotherapy that uses a patient’s own genetically modified T cells to find and kill cancer cells. In addition to FDA-approved therapies, we offer several ongoing clinical trials utilizing CAR T-cell therapy.
T cells are a type of white blood cell that can fight infection and disease. When a T cell recognizes something as a threat – like a cell infected by a virus – it attacks and destroys it to help keep the body healthy. The goal of CAR T-cell therapy is to direct T cells to cancer cells instead of cells that are infected.
During CAR T-cell therapy, a patient’s own T cells are extracted and genetically modified to express a chimeric antigen receptor, or CAR, that recognizes a protein on the surface of the cancer cells. Once the cells are modified, they’re also multiplied to increase in number over the course of two to three weeks.
The modified T cells are then infused back into the patient, where they will hopefully identify and destroy cancer cells. Because CAR T-cell therapy can cause serious side effects, patients remain in the hospital for one to two weeks following the infusion for monitoring.
To refer a patient for evaluation for one of these clinical trials, please call 1-833-876-2227.
If you think you might be a candidate for one of these clinical trials, please call 1-833-876-2227.
FDA-Approved Therapy
UPMC Hillman Cancer Center offers the FDA-approved therapies YESCARTA™ (axicabtagene ciloleucel) and KYMRIAH™ (tisagenlecleucel).
Learn MoreResearch and Clinical Trials
UPMC Hillman Cancer Center is currently enrolling patients in CAR T-cell therapy clinical trials.
Learn More